With over 20 years of expertise in the global animal health sector, Dr. Hasenmaier is a highly skilled commercial leader. He served in a number of high-level positions in Boehringer Ingelheim’s animal health division from 2001 to 2019, ultimately joining the board of managing directors, which is in charge of the division as a whole. He oversaw major product introductions, accelerated global development and expansion, and the integration of the former Sanofi animal health company Merial, among other successful transformation projects.
The Chairman of ECO, Dr. Andrew Jones, stated: He was delighted to welcome Joachim as a Non-Executive Director to ECO on behalf of the Board. With a plethora of industry and board expertise, he was certain that the company would greatly benefit from his proven track record of increasing sales and improving performance. As we seek to maximize the potential of our diverse commercial and R&D portfolio and grow our company both naturally and through new opportunities, we are enthusiastic about what 2024 has in store.
The new non-executive director of ECO, Dr. Joachim Hasenmaier, stated: ECO Animal Health is at a pivotal time in its development. The company’s innovative and targeted pipeline of biologics and vaccines positions it well to take advantage of future growth prospects. As a renowned pioneer in the animal health field, he looks forward to collaborating closely with the Board to spearhead the company’s next stage of expansion.
In addition, Dr. Hasenmaier has been a member of the Invetx Supervisory Boards and the Chairman of the Board at IMV Technologies since 2022. Before Heska was purchased by Mars Petcare, he was a member of the board of the NASDAQ-listed company. He was also a senior manager at McKinsey & Company and Hoechst Roussel Vet.
Dr. Hasenmaier is a veterinarian who graduated from Ludwig-Maximillians University in Munich with a PhD in immunology. possesses an MBA from USA’s Northwestern University.
